CD274 and familial pancreatic carcinoma: In a basket trial evaluating the safety and efficacy of an anti-PD-L1 antibody, none of the 14 patients with advanced pancreatic cancer experienced an objective response (Brahmer et al. 2012) however interim results of a multicentre, dose-expansion, phase I trial of the anti–PD-L1 monoclonal antibody durvalumab showed a disease control rate of 21% among 29 patients, 2 of whom achieved a partial response (Khalil and Segal 2016).